Effect of a High‐Fat Diet on the Pharmacokinetics and Safety of Rivaroxaban in Healthy Chinese Subjects

The effects of food on the pharmacokinetics (PKs) and safety of 10‐mg rivaroxaban tablets in healthy Chinese subjects were investigated from 1 bioequivalence trial. The bioequivalence trial was designed as randomized, open‐label, 2‐sequence, 4‐period crossover under both fasted and fed conditions. A total of 56 healthy subjects were enrolled, 62.5% were male. These subjects received a single oral 10‐mg dose of rivaroxaban with a 7‐day washout between 4 periods. Serial PK samples were collected and plasma concentrations were analyzed using validated high‐performance liquid chromatography–mass spectrometry. Pharmacokinetic parameters were calculated by noncompartmental methods. The BE module of WinNonLin was used for statistical analysis of the maximum concentration (C max ), the area under the concentration–time curve from zero to the final measurable concentration (AUC 0‐t ), and the area under the concentration–time curve from time zero to infinity (AUC 0‐∞ ) of rivaroxaban in plasma. Compared with the fasted state, the C max , AUC 0‐t , and AUC 0‐∞ of rivaroxaban significantly increased by 47%, 28%, and 26%, respectively, with oral administration of rivaroxaban 10 mg in the fed state. The incidence of adverse events (AEs) was similar between the fasted and fed states, and no serious AEs were observed. Food significantly increased the exposure to rivaroxaban 10 mg in Chinese subjects.